Recombinant CEACAM5 & CD3E (Cibisatamab Biosimilar) anticorps
Aperçu rapide pour Recombinant CEACAM5 & CD3E (Cibisatamab Biosimilar) anticorps (ABIN7538087)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Application
Classe de qualité
-
-
Expression System
- Mammalian cells
-
Fonction
- Cibisatamab Biosimilar – Anti-CEACAM5 & CD3E mAb - Research Grade
-
Attributs du produit
- Antibody Type: Bispecific mAb with Domain Crossover
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Pureté
- > 85%
-
Isotype
- IgG1 kappa, IgG1 lambda
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS buffer PH7.5
-
Stock
- -80 °C
-
Stockage commentaire
- store at -80°C
-
-
- CEACAM5 & CD3E (Cibisatamab Biosimilar)
-
Classe de substances
- Biosimilar
-
Sujet
- Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research.
-
Numéro CAS
- 1855925-27-7
Antigène
-